Merck & Co., Inc. (NYSE:MRK) is one of the top cheap pharmaceutical stocks to buy now. Goldman Sachs analyst Asad Haider ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently talked about. Cramer mentioned the stock and said that ...

Drug maker Merck announced Tuesday it will embark on an initiative to cut $3 billion in costs 2027, including an undisclosed ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

The stock's rise snapped a four-day losing streak.

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Merck is undergoing a strategic restructuring, resulting in immediate job cuts in administration, sales, and research as part of a plan to save $3 billion by 2027.

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a treatment for COPD -- to its portfolio. One of the biggest concerns with ...